June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada. SpectronRx has secured more than 10-acres in Bunker Hill, Indiana, where it is building a facility that will produce Actinium-225 for the clinical trial and commercial supply of cancer-fighting therapies.
“Although there’s currently no Food and Drug Administration-approved treatment using Ac-225, it’s showing great promise when it comes to the treatment of certain types of cancer, including prostate, breast, colon, brain and neuroendocrine,” said John Zehner, CEO of SpectronRx. “Researchers have been studying the radioisotope’s cancer-fighting potential for decades and are on the cusp of several new breakthroughs. Our goal is to support these new therapies as they are approved.”
Actinium-225 is an exceptional cancer fighter. It can be attached to a molecule that delivers the radionuclide to a selectively targeted cancer site, where the Ac-225 alpha-emission can destroy the cancerous tissue with minimum damage to healthy cells. And the high-energy alpha particles Ac-225 releases can interrupt DNA processes, keeping cancer cells from replicating or even killing them altogether. This makes Ac-225 one of the most promising candidates for targeted alpha therapy.
“Unfortunately, there is a limited supply of the Ac-225 radionuclide globally,” said Anwer Rizvi, president of SpectronRx. “This limits the ability of pharmaceutical companies to perform the drug trials needed in order to advance the use of this crucial radionuclide. That’s why building up production of Ac-225 is so important.”
Currently, only small amounts of Ac-225 are being produced by various government entities. To enhance the available supply, SpectronRx will produce Ac-225 through methods including the use of particle accelerators. The company will invest several million dollars to install multiple particle accelerators at its new site near Grissom Air Reserve Base in Indiana, which will produce the much-needed medical isotopes to treat cancer. The project is expected to take two years to complete.
For more information: SpectronRx.com
July 30, 2024 
